Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02659891 · ClinicalTrials.gov registry record · Phase 1
IVIg to Treat BK Viremia in Kidney Transplant Recipients
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT02659891: Completed Phase 1 study, sponsored by Massachusetts General Hospital.
NCT02659891 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02659891, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The overall goal of this study is to rapidly improve clearance of BK viremia with Immunoglobulin (Privigen®) thereby decreasing the potential for formation of alloantibodies in renal transplant recipients that have had immunosuppression reduction due to BK viremia. Our approach is to perform a prospective, randomized, placebo controlled trial intravenous immune globulin (IVIg; Privigen®) plus protocolized immunosuppression reduction versus placebo and protocolized immunosuppression reduction in patients with BK viremia post-kidney transplantation.
Interventions
- OTHER Placebo
- BIOLOGICAL IVIg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2016-05 |
| Est. Completion | 2021-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02659891
The ClinicalTrials.gov registry entry for NCT02659891 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02659891 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02659891 about?
NCT02659891 is a clinical study titled "IVIg to Treat BK Viremia in Kidney Transplant Recipients". The overall goal of this study is to rapidly improve clearance of BK viremia with Immunoglobulin (Privigen®) thereby decreasing the potential for formation of alloantibodies in renal transplant recipients that have had immunosuppression reduction due to BK viremia. Our approach is to perform a prosp...
What is the current status of trial NCT02659891?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2016-05. Estimated completion is 2021-03-31.
What interventions are being tested in trial NCT02659891?
The interventions under investigation include: Placebo (OTHER), IVIg (BIOLOGICAL).
Who is sponsoring clinical trial NCT02659891?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.